Powder: -20°C for 3 years
In solvent: -80°C for 2 years
TAK-615 is commonly used to study pulmonary fibrosis and is a negative allosteric modulator of LPA1 receptors.
Description | TAK-615 is commonly used to study pulmonary fibrosis and is a negative allosteric modulator of LPA1 receptors. |
In vitro | TAK-615 specifically binds to membranes expressing the human LPA1 receptor with estimated Kd high affinity of 1.7 ± 0.5 nM and Kd low affinity of 14.5 ± 12.1 nM. TAK-615 is only able to partically inhibit the LPA response (~40% at 10 μM with an IC50 of 23 ± 13 nM in β-arrestin assay; 60% at 10 μM, IC50 of 91 ± 30 nM in calcuim mobilisation assay). [1] |
Molecular Weight | 419.44 |
Formula | C25H22FNO4 |
CAS No. | 1664335-55-0 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 120 mg/mL (286.10 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TAK-615 1664335-55-0 GPCR/G Protein LPA Receptor LPA1 fibrosis LPL Receptor Lysophospholipid Receptor TAK615 modulator NAM inhibit pulmonary Inhibitor allosteric TAK 615 negative inhibitor